若生智能
Drug Database
IB

ibrutinib

✓ Approved

Johnson & Johnson Services, Inc. · 辅助诊断 · 辅助诊断

什么是 ibrutinib？

ibrutinib 是一种辅助诊断，由Johnson & Johnson Services, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

公司Johnson & Johnson Services, Inc.
药物类别辅助诊断
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Johnson & Johnson Services, Inc.

治疗适应症

ibrutinib 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedBMC pulmonary medicine2026-06-13

Diagnostic value of EBUS-TBNA for intrathoracic tuberculous lymphadenitis: a retrospective cohort analysis stratified by anti-tuberculosis treatment duration.

Bai Zhexin Z, Sun Zeyi Z, Dong Yujie Y, Nie Wenjuan W et al.

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is widely adopted to diagnose intrathoracic lymphadenopathy, including tuberculous lymphadenitis (TBLA). However, the influence of anti-tuberculosis (anti-TB) treatment duration on its diagnostic yield remains unclear. In this retrospective cohort study, 78patients with suspected intrathoracic TBLA who underwent EBUS-TBNA between June 2017 and January 2024 were included. Patients were categorized into four groups by prior anti-TB treatment duration. Composite diagnostic criteria incorporating histopathology, microbiology, and treatment response were used as the reference standard. Diagnostic performance across lymph node stations and modalities was analyzed. Safety outcomes were also evaluated. The overall diagnostic sensitivity of EBUS-TBNA based on composite criteria was 96.2%. Stratified analysis showed no statistically significant difference in diagnostic positivity among untreated (95.9%), 1-30 days (83.3%), 31-180 days (100%), and > 180 days (100%) groups (P = 0.42). Diagnostic yield was consistent across mediastinal, hilar, and combined lymph node stations (P = 0.289). Among diagnostic modalities, TB-DNA, histopathology TB-SPOT and sputum Xpert demonstrated high positivity rates. No major complications occurred; minor self-limited bleeding was observed in 15.4% of patients. EBUS-TBNA is a safe and effective diagnostic tool for intrathoracic TBLA, with consistent performance in both treatment-naïve and pretreated patients, regardless of anti-TB therapy duration.

PMID 42286605
阅读全文 →
PubMedBMC pulmonary medicine2026-06-13

Incremental contribution of bronchoalveolar lavage fluid data to multidisciplinary discussion of interstitial lung disease.

Peixoto Bianca B, Graça Nadja Polisseni NP, Dos Reis Visconti Nina Rocha Godinho NRG, de Carvalho Bethlem Marcos M et al.

Multidisciplinary discussion (MDD) integrating clinical, radiological, and laboratory information is considered the reference standard for the diagnosis of interstitial lung disease (ILD). Bronchoalveolar lavage fluid (BALF) analysis is recommended in several diagnostic algorithms, but its incremental contribution during multidisciplinary evaluation remains incompletely characterized. In this study, we aimed to assess the impact of BALF findings on diagnostic consensus and confidence during MDD for suspected ILD. In this cross-sectional study, patients with suspected ILD at a tertiary referral center who remained without a definitive diagnosis after clinical evaluation and high-resolution computed tomography (HRCT) underwent bronchoscopy with BALF collection (n = 29). Blinded pulmonologists and radiologists evaluated each case using a sequential four-step framework: (1) radiological assessment; (2) radiological assessment with clinical data; (3) multidisciplinary discussion without BALF information; and (4) multidisciplinary discussion including BALF results. Interobserver agreement was assessed using Fleiss' kappa, and diagnostic confidence was recorded at each stage. Diagnostic agreement increased across the sequential evaluation steps (Fleiss' κ: 0.056, 0.565, 0.905, and 0.965, respectively; p < 0.001). Consensus diagnoses were achieved in 24 cases after MDD without BALF and in 27 cases following incorporation of BALF findings. The proportion of evaluations with high diagnostic confidence (≥ 90%) increased from 3.4% before BALF availability to 20.7% after its inclusion. Within a multidisciplinary diagnostic framework for ILD, BALF information were associated with improved diagnostic consensus and increased clinician confidence. BALF may therefore serve as a complementary diagnostic tool in the multidisciplinary assessment of ILD, particularly in cases that remained uncertain after clinical and radiological evaluation.

PMID 42286572
阅读全文 →
PubMedCroatian medical journal2026-06-13

Artificial intelligence in pathology: a framework for preserving brain capital in the diagnostic apex.

Hart Steven N SN

To present a five-criterion calibration framework for evaluating artificial intelligence (AI) tools in pathology centered on preserving "brain capital" - the finite cognitive resources available to clinicians - and stabilizing the "diagnostic apex," the point where histological evidence meets clinical judgment. Using cognitive load theory (CLT) and implementation science, we developed the Pathology AI Diagnostic Balance - a conceptual model mapping the physician-specimen interaction within working memory and IT infrastructure constraints - and examined it in the context of peer-reviewed case studies of implemented pathology AI tools. The framework identifies five criteria: Contextual Literacy (integration of clinical history), Responsibility (preservation of signing authority), Evidence Gap Analysis (closure of diagnostic uncertainty), Verification (feasibility of quality control), and Opportunity Cost (return on cognitive investment). Successful tools, such as Ki-67 quantification and breast cancer screening, reduce cognitive burden by automating routine tasks or enabling rapid verification. Conversely, tools requiring an exhaustive re-review or producing opaque recommendations deplete cognitive bandwidth, causing decision fatigue and diagnostic errors. Pathologists are positioned to exercise evaluative authority over tools that increase extraneous cognitive load. Clinical expertise represents pathologists' most distinctive contribution to AI development: defining which failure modes matter clinically, what context an AI must integrate, and whether a tool serves patient care. By prioritizing cognitive sustainability over purely technical metrics, the profession can ensure AI functions as a genuine enhancement of diagnostic capability rather than an additional burden on diagnostic workflows.

PMID 42286907
阅读全文 →
PubMedGenetics research2026-06-13

Identification of Genetic Diagnostic Markers for Systemic Lupus Erythematosus.

Liu Qianqian Q, Yang Hairong H, Dang Chunxiao C, Song Xingxing X

Systemic lupus erythematosus (SLE) is a complex and heterogeneous systemic autoimmune disease associated with poor treatment outcomes. While previous studies have indicated a genetic predisposition to SLE, the underlying mechanisms remain poorly understood. This study aimed to identify diagnostic targets with potential genetic associations to SLE by leveraging bioinformatics and the Mendelian randomization (MR) approach. Six datasets (GSE30153, GSE39088, GSE50635, GSE50772, GSE61635, and GSE110169) were obtained from the GEO database for differential expression analysis to identify differentially expressed genes (DEGs). Weighted gene coexpression network analysis (WGCNA) was then performed, and the most relevant module was intersected with the DEGs to identify candidate genes with potential diagnostic value. Subsequently, machine learning algorithms were applied to screen diagnostic genes, and their performance was evaluated using receiver operating characteristic (ROC) curves and confusion matrices. MR analysis was conducted to identify diagnostic genes with genetic associations. A protein-protein interaction (PPI) network was constructed to identify core genes. Finally, gene set enrichment analysis (GSEA), gene set variation analysis (GSVA), and immune infiltration analysis were performed. Differential expression analysis identified 244 DEGs, and WGCNA revealed a highly relevant module. Intersecting this module with the DEGs produced 136 candidate genes. Machine learning algorithms and MR analysis further refined the selection, identifying five diagnostic genes: GBP1, IFI6, KLHDC8B, OAS3, and ZCCHC2, all of which were shown to be well-aligned with their respective drugs. The PPI network highlighted GBP1, IFI6, and OAS3 as core genes, which showed significant correlations with immune cell infiltration. Our study identified GBP1, IFI6, and OAS3 as core genes implicated in SLE pathogenesis, providing novel insights into its molecular mechanisms and potential therapeutic targets.

PMID 42286429
阅读全文 →
PubMedBMJ open2026-06-13

Accuracy of ophthalmic referral diagnoses by non-ophthalmologists in acute eye care: protocol for a systematic review and meta-analysis.

Cunha Gil Luis L, Powis Anaya A, Wilson Helen H, Thampy Reshma R et al.

Ophthalmic complaints account for a substantial proportion of presentations to emergency and acute eye care services, yet initial assessment or referral is frequently performed by non-ophthalmologist healthcare professionals. Previous single-centre studies suggest that one-third of referrals are incorrectly diagnosed, potentially delaying appropriate management of vision-threatening conditions. However, the overall magnitude of diagnostic error and patterns of misdiagnosis across healthcare settings remain unclear. This study aims to systematically review and synthesise the evidence on the diagnostic concordance of ophthalmic referral diagnoses made by non-ophthalmologists in acute eye care. A systematic review and meta-analysis will be conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols) guidance and registered with PROSPERO. MEDLINE (Ovid), Embase (Ovid) and the Cochrane CENTRAL database will be searched from inception to April 2025. Studies evaluating the diagnostic accuracy of referrals made by non-ophthalmologist healthcare professionals in emergency or acute eye care settings will be included. Two reviewers will independently screen studies, extract data and assess risk of bias using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) framework adapted for referral-diagnosis studies. The primary outcome will be diagnostic concordance between referral and final ophthalmologist diagnosis. Where appropriate, pooled concordance proportions will be synthesised using a random-effects meta-analysis. Condition-specific 2×2 diagnostic accuracy analyses will only be undertaken where valid binary target conditions and sufficient denominators are reported. Heterogeneity will be assessed using Cochran's Q test and the I² statistic with subgroup analyses exploring differences by referring clinician type and anatomical location of ophthalmic pathology. Ethical approval is not required for this study as it will synthesise data from previously published studies; findings will be disseminated through publication in a peer-reviewed journal and presentation at relevant academic conferences. CRD420261352717.

PMID 42285581
阅读全文 →
PubMedBMJ paediatrics open2026-06-13

Chinese expert consensus on the diagnostic definition of cerebral palsy.

Jiang Wei W, Zhu Dengna D, Tang Xiang X, Xu Kaishou K et al.

To standardise the diagnostic criteria for cerebral palsy (CP) in China by resolving key ambiguities surrounding the timing of brain injury, the definition of non-progressiveness and the role of genetic aetiologies. A modified Delphi process was conducted in 2025 by the Rehabilitation Subspecialty Group of the Chinese Pediatric Society. Thirty-three national experts in paediatric neurology, rehabilitation, genetics and epidemiology participated. The process included literature review, iterative statement drafting and two rounds of anonymous voting. Consensus was defined as ≥80% agreement. Three diagnostic pillars were established: (1) a non-progressive injury to the developing brain occurring from the embryonic period through age 3; (2) non-progressive nature is defined by the absence of regression of previously acquired motor milestones through age 5 and (3) genetic factors are integral to CP pathogenesis and may justify classification as 'CP due to genetic variation' when specific criteria are met. Cerebral MRI, General Movements Assessment and Hammersmith Infant Neurological Examination were highlighted as key tools for early diagnosis. This updated expert consensus aligns national CP diagnostic criteria with current advances in neurodevelopmental and genomic science. It supports early, accurate diagnosis, guides genetic evaluation and promotes harmonised clinical practice across Chinese healthcare systems.

PMID 42285613
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多ibrutinib